Vitamin D Council needs your help...

Tax-deductible!

Together we can end the illness and disease caused by the worldwide epidemic of vitamin D deficiency.

About Vitamin D Council

Contact Vitamin D Council

Sponsor Vitamin D Council

Follow us on:

Vitamin D Products

(off-site)

These companies donate to the Vitamin D Council.

D-Lite, Renew, & SunSplash UV/Tanning Systems
In-Home ZRT Vitamin D Blood Test Kit
Get Premium Quality Vitamin D Supplements at Great Prices
Vitamin D3 Plus™ from Bio-Tech — contains the cofactors Vitamin D needs to work properly.

Vitamin D Research

back to research menu

HIV and AIDS

Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania. J Infect Dis. 2009 Oct 1;200(7):1022–30.
No influence of nevirapine on vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses. 2009 Aug;25(8):849–50.
Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009 Jun;75(6):1392–9.
Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009 May 1;179(9):843–50.
Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome? AIDS Res Ther. 2009 Apr 21;6(1):4.
Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009 Mar;15(2):559–65.
5' regulatory and 3' untranslated region polymorphisms of vitamin D receptor gene in south Indian HIV and HIV-TB patients. J Clin Immunol. 2009 Mar;29(2):196–204.
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009 Jan 2;23(1):51–7.
High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009 Jan;25(1):9–14.
Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol. 2009 Jan;81(1):16–26.
Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009 Jan;123(1):e121–6.
Prediction of interactions between HIV-1 and human proteins by information integration. Pac Symp Biocomput. 2009:516–27.
Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. J Nutr. 2008 Dec;138(12):2474–80.
Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia. Sex Health. 2008 Dec;5(4):375–6.
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375–82.
The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med. 2008 Oct;9(9):771–9.
Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008 Aug;23(8):1304–8.
Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer. 2008 Jun 15;122(12):2842–50.
Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother. 2008 May;42(5):670–9. Review.
Growth hormone and bone mineral densitiy in HIV-1-infected male subjects. Eur J Med Res. 2008 Apr 30;13(4):173–8.
The Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 24 Months. J Bone Miner Res. 2008 Mar 18.
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos. 2008 Mar;36(3):500–7.
Vitamin D intoxication: a cause of hypocalcaemia and acute renal failure in a HIV patient. Int J STD AIDS. 2008 Feb;19(2):137–8.
Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J Infect Dis. 2008 Feb 1;197(3):405–10.
Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest. 2008 Feb;88(2):171–84.
Hemophilia, low bone mass, and osteopenia/osteoporosis. Transfus Apher Sci. 2008 Feb;38(1):33–40. Review.
Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. Ann Clin Microbiol Antimicrob. 2008 Jan 28;7:3.
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007 Nov 30;21(18):2473–82.
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res. 2007 Nov;6(11):4189–99.
Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr. 2007 Nov;119(21–22):639–646.
Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child. J Pediatr Endocrinol Metab. 2007 Aug;20(8):933–8.
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read. 2007 Jun;17(6):322–8, C3.
Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3. J Mol Endocrinol. 2007 Jun;38(6):587–601.
Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005645. Review.
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007 Apr;92(4):1283–8.
Influence of candidate susceptibility genes on tuberculosis in a high endemic region. Mol Immunol. 2007 Mar;44(9):2213–20.
Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006 Dec 1;85(3):258–62.
Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006 Oct;372(1–2):33–42. Review.
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006 Sep 11;20(14):1906–7.
HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. Leuk Res. 2006 Aug;30(8):1005–11.
Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006 Jul;25(4):537–9.
Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical management. Curr Mol Med. 2006 Jun;6(4):395–400. Review.
Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006 May;83(5):1135–41.
A potential role for vitamin D on HIV infection? Nutr Rev. 2006 May;64(5 Pt 1):226–33. Review.
Drug-induced renal calculi. Ann Urol (Paris). 2006 Apr;40(2):57–68. Review.
Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Res Hum Retroviruses. 2006 Feb;22(2):125–31.
Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005 Nov;21(11):915–21.
Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005 Nov;16(11):1345–52.
Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339–46.
The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ. 2005 Aug;12 Suppl 1:991–8. Review.
Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005 May;6(3):145–50.
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):426–31.
The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol. 2004 Dec;10(6):327–37.
Bone disorders associated with the human immunodeficiency virus: pathogenesis and management. Pharmacotherapy. 2004 Oct;24(10):1331–46. Review.
Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi. Am J Trop Med Hyg. 2004 Sep;71(3):341–9.
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 2004 Sep–Oct;5(5):269–77.
Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients. J Steroid Biochem Mol Biol. 2004 May;89–90(1–5):199–207.
Are WHO/UNAIDS/UNICEF-recommended replacement milks for infants of HIV-infected mothers appropriate in the South African context? Bull World Health Organ. 2004 Mar;82(3):164–71.
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004 Mar;48(1):39–48.
Calcium and bone mineral metabolism in children with chronic illnesses. Annu Rev Nutr. 2004;24:13–32. Review.
Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245–75. Review.
An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome. Int J Med Sci. 2004;1(3):152–164.
Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):467–74.
Two cases of hypocalcemia secondary to vitamin D deficiency in an urban HIV-positive pediatric population. AIDS. 2003 Nov 7;17(16):2401–3.
Tuberculosis in compromised hosts. Kekkaku. 2003 Nov;78(11):717–22.
HIV infection—a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):281–91. Review.
Bone dysmetabolism in HIV infection: a melting pot of opinions. AIDS. 2003 Jun 13;17(9):1416–7.
Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003 May;46(4):221–7.
Fat redistribution and bone abnormalities in HIV-infected patients. J Int Assoc Physicians AIDS Care (Chic Ill). 2003 Apr–Jun;2(2):59–65. Review.
Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003 Apr 1;36(Suppl 2):S101–5.
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003 Mar 7;17(4):513–20.
Correlation between normal modes in the 20-200 cm-1 frequency range and localized torsion motions related to certain collective motions in proteins. J Mol Graph Model. 2003 Jan;21(4):309–19.
Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutr Hosp. 2002 Nov–Dec;17(6):285–9.
Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity. Pharm Res. 2002 Nov;19(11):1696–703.
Tuberculosis and vitamin D deficiency. J Assoc Physicians India. 2002 Apr;50:554–8.
Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users. J Infect Dis. 2001 Nov 15;184(10):1279–88.
Hypercalcaemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J Infect. 2001 Feb;42(2):157–8.
Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res. 2001 Jan;16(1):2–9. Review.
Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism. 2000 Sep;49(9):1134–9.
Side effects. Bone problems and anti-HIV therapy. TreatmentUpdate. 2000 Aug;12(5):4–5.
Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310–8.
Hypercalcemia associated with infection by Cryptococcus neoformans and Coccidioides immitis. Am J Med Sci. 1999 Dec;318(6):419–23.
Drug-induced urinary calculi in 1999. Prog Urol. 1999 Dec;9(6):1023–33. Review.
Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients. J Nephrol. 1999 Nov–Dec;12(6):398–403.
Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology. 1999 May;116(5):1115–23.
Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa: anthropometric and dietary profile. Eur J Clin Nutr. 1999 Mar;53(3):165–73.
Hypocalcaemia in HIV infection and AIDS. J Intern Med. 1999 Jan;245(1):69–73.
Paroxysmal dyskinesias in patients with HIV infection. Neurology. 1999 Jan 1;52(1):109–14.
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998 Nov;83(11):3832–8.
Different effect of 1,25-dihydroxyvitamin D3 on replication of Mycobacterium avium in monocyte-derived macrophages from human immunodeficiency virus-infected subjects and healthy controls. Immunol Lett. 1998 Sep;63(2):107–12.
The immunogenetics of human infectious diseases. Annu Rev Immunol. 1998;16:593–617. Review.
Hypercalcemia in an AIDS patient treated with growth hormone. AIDS. 1997 Sep;11(11):1353–6.
Parvalbumin and calbindin D-28 k immunoreactivity in dorsal root ganglia in acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol. 1996 Aug;22(4):293–301.
The effect of 1,25-vitamin D3 on maturation of monocytes from HIV-infected patients varies with degree of immunodeficiency. APMIS. 1996 Jul–Aug;104(7–8):539–48.
Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. APMIS. 1996 Jul–Aug;104(7–8):539–48.
Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res Hum Retroviruses. 1995 Nov;11(11):1373–8.
Calbindin D28K-containing neurons, and not HSP70-expressing neurons, are more resistant to HIV-1 envelope (gp120) toxicity in cortical cell cultures. J Neurosci Res. 1995 Oct 1;42(2):252–8.
Differential vulnerability of calbindin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol. 1995 May;54(3):350–7.
Update on vitamins, minerals, and the carotenoids. J Physicians Assoc AIDS Care. 1995 Jan;2(1):24–9.
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994 Apr;169(4):889–93.
Vitamin D and the immune system. Pathol Biol (Paris). 1994 Feb;42(2):163–72. Review.
The relationship between tuberculosis, vitamin D, potassium and AIDS. A message for South Africa? S Afr Med J. 1994 Feb;84(2):79–82.
Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci. 1993 Nov;306(5):313–6.
Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2984–8.
HIV cofactors in the course of AIDS. Presse Med. 1992 Sep 19;21(30):1426–30. Review.
The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol. 1992 Sep;17(5):342–3.
GC subtyping and HIV infection in a Spanish population: no evidence of an association between GC subtypes and AIDS. Clin Exp Dermatol. 1992 Sep;17(5):342–3.
The potential role of nutritional factors in the induction of immunologic abnormalities in HIV-positive homosexual men. J Acquir Immune Defic Syndr. 1989;2(3):235–47. Review.
Group specific component (Gc) and HIV diseases. Dis Markers. 1988 Oct–Dec;6(4):269–74.
No predictive value of GC phenotypes for HIV infection and progression to AIDS. Hum Genet. 1988 Oct;80(2):181–2.
Group specific component and susceptibility to acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. Haematologica. 1988 Sep–Oct;73(5):371–3.
The group-specific protein marker: a possible indicator of syphilis, not human immunodeficiency virus infection. Haematologica. 1988 Sep–Oct;73(5):371–3.
HIV infection and distribution of GC alleles in AIDS patients, i.v. drug addicts, and hemophiliacs. Beitr Infusionsther. 1988;21:169–73.
AIDS: no association with the genetic systems GC (D-binding protein), ORM (orosomucoid = alpha-1-acid glycoprotein), and A2HS (alpha-2-HS-glycoprotein). Infection. 1988;16(1):31–5.
Group specific component and susceptibility to HIV infection and progression to AIDS. Scand J Infect Dis. 1988;20(1):11–4.
HIV infection and Gc: absence of relationship. AIDS. 1987 Dec;1(4):258–9.
Gc serum groups, HIV and AIDS. Dtsch Med Wochenschr. 1987 Oct 9;112(41):1597.
Group-specific component and HIV infection. Lancet. 1987 Aug 1;2(8553):282–3.
Group-specific component and HIV infection. Lancet. 1987 Jul 4;2(8549):39–40.
Group specific component and HIV infection. Lancet. 1987 May 30;1(8544):1267–9.
Association of different allelic forms of group specific component with susceptibility to and clinical manifestation of human immunodeficiency virus infection. Lancet. 1987 May 2;1(8540):999–1002.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.